We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cerno Bioscience Signs Agreements with Leading Pharmaceutical Research Programs in Shanghai
News

Cerno Bioscience Signs Agreements with Leading Pharmaceutical Research Programs in Shanghai

Cerno Bioscience Signs Agreements with Leading Pharmaceutical Research Programs in Shanghai
News

Cerno Bioscience Signs Agreements with Leading Pharmaceutical Research Programs in Shanghai

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cerno Bioscience Signs Agreements with Leading Pharmaceutical Research Programs in Shanghai"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cerno Bioscience announces two major agreements have been reached with leading research institutes in China for the use of its MS data analysis software, MassWorks™.

Cerno has entered into collaborative research in drug metabolism with Dr Dafang Zhong, Director of Drug Metabolism Research at Shanghai Institute of Materia Media, Chinese Academy of Sciences. Cerno has also signed an agreement with Egret Pharma (Shanghai) Limited for extensive use of the MassWorks software in small molecule synthesis.

Research by Dr Zhong will focus on obtaining high mass accuracy to aid in metabolite identification using conventional mass spectrometry systems by applying MassWorks.  The triple quadrupole systems are specified to provide only rudimentary mass accuracy and therefore lack the high mass accuracy capabilities of a high resolution system considered necessary for metabolite identification. 

Metabolism researchers will be able to achieve the results of a high-end spectrometer for a fraction of the investment when applying MassWorks’ MSIntegrityTM calibration technology, which improves mass accuracy by up to 100x.  In addition to enhancing and confirming the identity of various metabolites, the software will also improve the signal-to-noise and peak shape of the MS data to further enable elemental composition determination on these unit mass resolution MS systems.

The agreement with Egret Pharma, a leading Chinese pharmaceutical research and development company, will see the company using Cerno’s MassWorks software extensively in its small molecule synthesis studies to significantly shorten the turn-around time in the drug discovery process.

 MassWorks will be used to confirm the identity of target compounds as well as to identify synthesis by-products, impurities and degradation products, all using conventional unit mass resolution MS systems.  This identification will provide timely feedback to the organic chemists to reduce turn-around time.

MassWorks utilizes Cerno’s DirectRead™ technology to read most instrument data formats directly, eliminating the need for importing or exporting MS data to the clipboard or utilizing intermediate exchange formats.

This saves time, reduces transcription errors, simplifies file management, and saves substantial disk space. As DirectRead does not alter the original data, it assists compliance with common regulatory requirements such as GLP and the FDA’s 21 CFR Part 11.

Advertisement